Skip to main content

Table 3 Univariate analysis for each of the 18 markers included in the full model of Figure 1

From: Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models

Variable 95% CI Pvalue
[Pathology]
Tumor size 1.064 1.200 0.0003
Age <50 years 0.959 2.075 0.0719
Nuclear grade 1.017 1.676 0.0353
Nodal status 1.717 3.456 2.3 × 10-7
ER (IHC) 0.709 0.926 0.0017
PR (IHC) 0.751 0.986 0.0281
HER2 (IHC) 1.018 1.379 0.0337
[AQUA]
AURKA 1.008 1.019 0.0001
BAG1 0.986 1.008 0.5826
BCL2 0.988 0.999 0.0084
BIRC5 0.999 1.023 0.0642
CCNB1 0.968 1.060 0.5854
CD68 0.975 1.017 0.6866
GRB7 1.006 1.019 0.0008
GSTM1 0.996 1.030 0.1412
KI67 0.994 1.041 0.1722
MMP11 0.996 1.018 0.2349
MYBL2 0.984 1.016 0.9950
  1. For each marker a univariate Cox proportional hazards model is fit to the data using the entire cohort. The 95% confidence interval (CI) is shown together with the log-likelihood test P value. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER) 2 were measured by immunohistochemistry (IHC).